Definitive radiotherapy for prostate cancer in Norway 2006–2015: Temporal trends, performance and survival

AbstractBackground More studies are needed to document nation-wide use and effectiveness of curative definitive radiotherapy (Def-RT) in the treatment prostate cancer (PCa). Patients methods For 38,960 men diagnosed with PCa without distant metastases from 2006 2015 data Norwegian Prostate Cancer Registry a national database (NoRadBase) was analyzed. Overall survival PCa-specific mortality were described comparing EQD-2 < 74 Gy ("low-dose") ≥ ("escalated dose"). Results Use Def-RT decreased (27–24%) whereas proportion radical prostatectomies (RPs) increased (31–38%). In high-risk patients RP doubled (18–36%), while remained stable (about 35%). Before 2010, almost quarter received low-dose gradual increase escalated thereafter. Escalated associated significantly more favorable 10-year (4.4% [95% CI: 2.7–10.7%]) than observed after Def- RT (8.8% 6.2–9.8%), most beneficial effects patients. Our analyses indicated need expand NoRadBase by consensus-based quality measures. Conclusion this nationwide cohort, overall slightly. provision accompanied doubling reduction "no treatment" strategy. dose reduced compared Def-RT. Aiming for care equity registries should regularly monitor based on measures enabling feedback responsible hospitals.